• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

The tumour-promoting receptor tyrosine kinase, EphB4, regulates expression of Integrin-β8 in prostate cancer cells
Conclusions: These results reveal that EphB4 regulates integrin β8 expression and that integrin β8 plays a hitherto unrecognized role in the motility of prostate cancer cells and thus targeting integrin β8 may be a new treatment strategy for prostate cancer.
Source: BMC Cancer - March 22, 2015 Category: Cancer & Oncology Authors: Inga Mertens-WalkerBruno FernandiniMohanan MaharajAnja RockstrohColleen NelsonAdrian HeringtonSally-Anne Stephenson Source Type: research

Curcumin analog WZ35 induced cell death via ROS-dependent ER stress and G2/M cell cycle arrest in human prostate cancer cells
Conclusions: Taken together, this work presents the novel anticancer candidate WZ35 for the treatment of prostate cancer, and importantly, reveals that increased ROS generation might be an effective strategy in human prostate cancer treatment.
Source: BMC Cancer - November 6, 2015 Category: Cancer & Oncology Authors: Xiuhua ZhangMinxiao ChenPeng ZouKarvannan KanchanaQiaoyou WengWenbo ChenPeng ZhongJiansong JiHuiping ZhouLangchong HeGuang Liang Source Type: research

Loss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer
Conclusions: These observations imply that the frequently noted loss-of-function of NKX3.1 cooperates with the activation of TMPRSS2-ERG fusions in prostate tumorigenesis.
Source: BMC Cancer - January 13, 2014 Category: Cancer & Oncology Authors: Rajesh ThangapazhamFrancisco SaenzShilpa KattaAhmed MohamedShyh-Han TanGyorgy PetrovicsShiv SrivastavaAlbert Dobi Source Type: research

Metformin anti-tumor effect via disruption of the MID1 translational regulator complex and AR downregulation in prostate cancer cells
Conclusions: Findings reported herein uncover a mechanism for the anti-tumor activity of metformin in prostate cancer, which is independent of its anti-diabetic effects. These data provide a rationale for the use of metformin in the treatment of hormone naive and castration-resistant prostate cancer and suggest AR is an important indirect target of metformin.
Source: BMC Cancer - January 31, 2014 Category: Cancer & Oncology Authors: Ummuhan DemirAndrea KoehlerRainer SchneiderSusann SchweigerHelmut Klocker Source Type: research

CDK11p58 inhibits ERalpha-positive breast cancer invasion by targeting integrin beta3 via the repression of ERalpha signaling
Conclusions: These data indicate that CDK11p58 is an anti-metastatic gene in ERalpha-positive breast cancer and that the regulation of integrin beta3 by CDK11p58 via the repression of ERalpha signaling may constitute part of a signaling pathway underlying breast cancer invasion.
Source: BMC Cancer - August 8, 2014 Category: Cancer & Oncology Authors: Yayun ChiSheng HuangLei WangRuoji ZhouLisha WangXiuying XiaoDali LiYing CaiXiaoyan ZhouJiong Wu Source Type: research

Cross-talk between alpha1D-adrenoceptors and transient receptor potential vanilloid type 1 triggers prostate cancer cell proliferation
Conclusions: We demonstrate a cross-talk between alpha1D-AR and TRPV1, that is involved in the control of PC3 cell proliferation. These data strongly support for a putative novel pharmacological approach in the treatment of PCa by targeting both alpha1D-AR and TRPV1 channels.
Source: BMC Cancer - December 7, 2014 Category: Cancer & Oncology Authors: Maria MorelliConsuelo AmantiniMassimo NabissiSonia LiberatiClaudio CardinaliValerio FarfarielloDaniele TomassoniWilma QuagliaAlessandro PiergentiliAlessandro BonifaziFabio Del BelloMatteo SantoniGabriele MammanaLucilla ServiAlessandra FilosaAngela Gismond Source Type: research